Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells

The development of a prophylactic vaccine for hepatitis C virus (HCV) remains a global health challenge. Cumulative evidence supports the importance of antibodies targeting the HCV E2 envelope glycoprotein to facilitate viral clearance. However, a significant challenge for a B cell-based vaccine is...

Descripción completa

Detalles Bibliográficos
Autores principales: Urbanowicz, Richard A., Wang, Ruixue, Schiel, John E., Keck, Zhen-yong, Kerzic, Melissa C., Lau, Patrick, Rangarajan, Sneha, Garagusi, Kyle J., Tan, Lei, Guest, Johnathan D., Ball, Jonathan K., Pierce, Brian G., Mariuzza, Roy A., Foung, Steven K. H., Fuerst, Thomas R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430559/
https://www.ncbi.nlm.nih.gov/pubmed/30651366
http://dx.doi.org/10.1128/JVI.01403-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430559/
https://www.ncbi.nlm.nih.gov/pubmed/30651366
http://dx.doi.org/10.1128/JVI.01403-18

Ejemplares similares